Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD8-targeted ADA-1 mRNA lipid nanoparticles
- Development stage
- Preclinical
- Lead developer
- Children's Hospital of Philadelphia
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
CD8-targeted ADA-1 mRNA lipid nanoparticles (CD8-ADA-LNPs) are preclinical-stage, targeted lipid nanoparticles designed to selectively deliver mRNA encoding adenosine deaminase-1 (ADA-1) to CD8+ T cells. Developed by researchers at Drexel University, the University of Pennsylvania, and collaborating institutions, this therapeutic approach aims to address the progressive dysfunction of HIV-specific CD8+ T cells in people living with HIV (PLWH). In PLWH, the adenosine-adenosine deaminase-1 axis is dysregulated, with repression of the ADA locus and heightened sensitivity to adenosine-mediated immunosuppression. By selectively delivering ADA-1 mRNA to CD8+ T cells, CD8-ADA-LNPs restore ADA-1 expression, degrade excess extracellular adenosine, and enhance antigen-specific CD8+ T-cell activation and function.
- Other names
- CD8-targeted adenosine deaminase-1 mRNA lipid nanoparticlesCD-8-targeted adenosine deaminase-1 mRNA lipid nanoparticlesCD 8-targeted adenosine deaminase-1 mRNA lipid nanoparticles
02
Targets
CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on CD8-targeted ADA-1 mRNA lipid nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD8-targeted ADA-1 mRNA lipid nanoparticles.